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Dora Buonfrate5, Alessandra Nicoletti3, Héctor Hugo Garcı́a6, Edoardo Pozio7, Alessandro Bartoloni1,2*,
The COHEMI Project Study Group"
1 Infectious Disease Unit, Department of Experimental and Clinical Medicine, University of Florence School of Medicine, Florence, Italy, 2 SOD Malattie Infettive e Tropicali,
Azienda Ospedaliero-Universitaria Careggi, Florence, Italy, 3 Department G.F. Ingrassia, Section of Neurosciences, University of Catania, Catania, Italy, 4 Servicio de
Medicina Tropical y Salud Internacional, Centre de Recerca en Salut Internacional de Barcelona, Hospital Clı́nic-Universitat de Barcelona, Barcelona, Spain, 5 Centre for
Tropical Diseases, Sacro Cuore Hospital, Via Don Sempreboni, Negrar (Verona), Italy, 6 Cysticercosis Unit, Instituto de Ciencias Neurologicas, Department of Microbiology,
Universidad Peruana Cayetano Heredia, Lima, Peru, 7 Department of Infectious, Parasitic and Immunomediated Diseases, Istituto Superiore di Sanità, Rome, Italy
Abstract
Background: Cysticercosis is caused by the invasion of human or pig tissues by the metacestode larval stage of Taenia
solium. In Europe, the disease was endemic in the past but the autochthonous natural life cycle of the parasite is currently
completed very rarely. Recently, imported cases have increased in parallel to the increased number of migrations and
international travels. The lack of specific surveillance systems for cysticercosis leads to underestimation of the
epidemiological and clinical impacts.
Objectives: To review the available data on epidemiology and management of cysticercosis in Europe.
Methods: A review of literature on human cysticercosis and T. solium taeniasis in Europe published between 1990–2011 was
conducted.
Results: Out of 846 cysticercosis cases described in the literature, 522 cases were autochthonous and 324 cases were
imported. The majority (70.1%) of the autochthonous cases were diagnosed in Portugal from 1983 and 1994. Imported
cases of which 242 (74.7%) diagnosed in migrants and 57 (17.6%) in European travellers, showed an increasing trend. Most
of imported cases were acquired in Latin America (69.8% of migrants and 44.0% of travellers). The majority of imported
cases were diagnosed in Spain (47.5%), France (16.7%) and Italy (8.3%). One third of neurosurgical procedures were
performed because the suspected diagnosis was cerebral neoplasm. Sixty eight autochthonous and 5 imported T. solium
taeniasis cases were reported.
Conclusions: Cysticercosis remains a challenge for European care providers, since they are often poorly aware of this
infection and have little familiarity in managing this disease. Cysticercosis should be included among mandatory reportable
diseases, in order to improve the accuracy of epidemiological information. European health care providers might benefit
from a transfer of knowledge from colleagues working in endemic areas and the development of shared diagnostic and
therapeutic processes would have impact on the quality of the European health systems. Key words: cysticercosis,
neurocysticercosis, Taenia solium, taeniasis, Europe, travellers, migrants.
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Introduction
Cysticercosis is due to the invasion of human or pig tissues by
the metacestode larval stage of Taenia solium [1], a helminth that
may reach of up to 8 m in length in the adult stage. T. solium is a
zoonotic cestode which has a complex two host life cycle [1].
Humans are the only definitive hosts, harbouring the adult
tapeworm in the gut without having significant symptoms [2]. The
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adult tapeworm is acquired by eating raw or undercooked pork
meat containing cysticerci [1]. Adult tapeworms have a life span of
some years during which they produce millions of eggs which are
intermittently released in the environment with the faeces [3–5].
Humans and pigs acquire cysticercosis ingesting T. solium eggs by
the fecal-oral route [1]. After the ingestion, embryos contained in
the eggs are released, cross the intestinal mucosa and are then
transported by the circulatory system and dispersed throughout
the body producing cysts mainly in the central nervous system
(CNS) and in striated muscles [1]. Pigs are usually infected when
reared in areas lacking adequate sanitary infrastructure where they
can feed on human faeces [6].
Humans can acquire cysticercosis ingesting T. solium eggs
released by themselves (autoinfestation) or by another tapeworm
carrier living with them or involved in the preparation of food
[7,8]. In humans, the CNS is the most frequent localization of
cysts which cause neurocysticercosis (NCC) [1]. NCC is consid-
ered to be the most common parasitic infection of the human
nervous system and the most frequent preventable cause of
epilepsy in the developing world [9] being responsible for about
30% of cases of epilepsy in low resources countries [10].
In several countries of Latin America, Africa and Asia,
cysticercosis is highly endemic and linked to poverty, ignorance,
lack of suitable diagnostic and management capacity and
appropriate prevention and control strategies [9]. In these areas,
cysticercosis leads to a very high economical burden related to
losses in the meat industry for porcine cysticercosis, hospitalization
costs for NCC and reduced productivity of people affected by
NCC [2,11,12]. The situation is quite different in high resources
countries such the United States and Europe. In the United States,
cysticercosis has always been predominantly an imported disease
and the number of observed cases increased from the 1970s
onwards following the rise of immigration and the wide availability
of the computerized tomography (CT) scan [13]. However in the
period 1954–2005, 78 autochthonous cases have been reported in
USA due to transmission from asymptomatic tapeworm carriers,
who most likely acquired the infection abroad, to their household
contacts [14].
In Europe, the disease was endemic in the past [15], but the
natural life cycle of the parasite is currently completed very rarely
thanks to the introduction of meat inspection, the progressive
improvement of the pig husbandry, of the hygienic and socio-
economic conditions and consumers education [15,16]. Autoch-
thonous cases of human and porcine cysticercosis are currently
reported very rarely in Europe [17,18], while human imported
cases emerged in the last two decades only when immigration from
low resource countries towards this continent became consistent
[19]. In Europe, cysticercosis is not covered by specific surveillance
systems. The epidemiology of the taeniasis/cysticercosis in high
resources countries is probably changing, but the lack of reliable
data is one of the major obstacles to understand the magnitude of
the problem and the relevance of the disease is probably
underestimated.
COHEMI (COordinating resources to assess and improve
HEalth status of MIgrants from Latin America) is a three-year
collaborative project supported by the European Commission
under the Health Cooperation Work Programme of the 7th
FRAMEWORK PROGRAMME (GA-261495) launched in 2011
(http://www.cohemi-project.eu/). The consortium brings together
ten partners, six from Europe and four from Latin America (LA).
One of the main objectives of the project is to provide a reliable
estimate of the burden of selected Neglected Tropical Diseases in
countries of origin and in different groups of migrants in Europe.
The aim of this study is to review, scientific and grey literature
on the epidemiology and management of autochthonous and
imported cases of cysticercosis and T. solium taeniasis in Europe.
Methods
A review of indexed and grey literature on cysticercosis and T.
solium taeniasis observed in Europe and published during the
period 1990–2011 (July) was conducted. The data analysis focused
on incidence and prevalence in the general population or special
group of subjects, age and sex, infection rates, major clinical
aspects, and country of infection.
The investigation covered 45 European countries, namely
Albania, Andorra, Austria, Belarus, Belgium, Bosnia Herzegovina,
Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia,
Finland, France, Germany, Greece, Hungary, Iceland, Ireland,
Italy, Latvia, Lithuania, Luxemburg, Macedonia, Malta, Monaco,
Moldova, Montenegro, Netherlands, Norway, Poland, Portugal,
Romania, Russia, San Marino, Serbia, Slovakia, Slovenia, Spain,
Sweden, Switzerland, Turkey, Ukraine, United Kingdom and
Vatican State.
Search
The following search strategy was adopted in PubMed (http://
www.ncbi.nlm.nih.gov/pubmed/), Embase (http://embase.com/
home), The Cochrane Library (http://www.thecochranelibrary.
com/): (cysticerc* OR neurocysticerc* OR cisticerc* OR neuro-
cisticerc* OR taenia* OR tenia* OR tapeworm) AND (Albania
OR Andorra OR Austria OR Belarus OR Belgium OR Bosnia
OR Herzegovina OR Bulgaria OR Cyprus OR Czech Republic
OR Denmark OR Estonia OR Finland OR France OR Germany
OR Greece OR Hungary OR Ireland OR Italy OR Latvia OR
Lithuania OR Luxemburg OR Malta OR Monaco OR Moldova
OR Netherlands OR Poland OR Portugal OR Romania OR San
Marino OR Serbia OR Slovakia OR Slovenia OR Spain OR
Sweden OR United Kingdom OR Ukraine OR Switzerland OR
Norway OR Russia OR Croatia OR Montenegro OR Iceland
OR Turkey OR Macedonia OR Vatican State OR Europe) AND
(Humans[Mesh] AND (‘‘1990/01/01’’[PDAT] : ‘‘2011/07/
31’’[PDAT])). The search has been performed in August 2011.
The online abstract book database of European Congress of
Clinical Microbiology and Infectious Diseases (ECCMID, http://
www.blackwellpublishing.com/eccmid/) from 2000 to 2010 were
also screened. Given the characteristics of the online abstract book
database of ECCMID, it was queried using the following keywords
‘‘cysticercosis’’, ‘‘neurocysticercosis’’ and ‘‘Taenia solium’’. More-
over, additional published and unpublished studies from the
authors were included together with data from the Ministry of
Health (MoH) of the European authors’ countries (Spain and Italy)
concerning the number of hospitalizations for cysticercosis in the
national territories according to ICD9CM codes, since very few
documents reported epidemiological data concerning cysticerco-
sis/T. solium taeniasis in Europe.
Selection
The authors screened articles found by electronic search and
evaluated their appropriateness based on title and abstract
according to the established criteria. Exclusion criteria were: 1)
studies concerning wrong agent (for example Taenia saginata or
Echinococcus spp.); 2) reviews, letters or editorials without original
data; 3) papers based on data only obtained through studies
aiming to evaluate the performance of laboratory tests; 4) studies
concerning animals only; 5) studies of European investigator
outside the continent; 6) duplicated data; 7) articles with full texts
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written in languages other than that at least one of the members of
the team could read and understand (namely English, French,
Italian, German and Spanish). If the eligibility of the documents
could not be ascertained according to the abstract and title only,
the full text was analyzed to exclude or include the document.
Moreover, in order to reduce possible underestimation of
cysticercosis/T. solium taeniasis burden in some countries (mainly
Eastern European countries), articles with an available English
abstract, initially excluded due to the language of the full text, were
selected as well.
Extraction
Data from epidemiological studies were summarized, while data
from case reports and case series were extracted using a
standardized electronic form in which the main characteristics of
study, clinical and epidemiological features of subjects with
cysticercosis and/or T. solium taeniasis were recorded. The form
included all the information needed to ascertain whether cases of
cysticercosis and of T. solium satisfied the definition of definitive,
probable or possible case (reported below). Concerning English
abstracts of articles initially excluded due to language limits, only
information contained in the abstract and referred to the number
of cases reported and the most likely place of infection was
extracted.
Cases of cysticercosis and T. solium taeniasis retrieved by the
search were classified according to the following definitions:
N Definitive or probable case of neurocysticercosis: according to the
criteria shown in Table 1, which were proposed by Del Brutto
[20]. A case confirmed through Polymerase Chain Reaction
(PCR) on bioptic specimen was also considered definitive;
N Definitive case of cysticercosis outside of CNS: case that was
histologically confirmed by the presence of one or more
cysticerci or PCR confirmed;
N Possible case of cysticercosis or neurocysticercosis: case reported by the
authors as ‘‘cases of neurocysticercosis or cysticercosis’’, but
not fulfilling the criteria of definitive or probable case (for
Table 1. Diagnostic criteria and degree of certainty for the diagnosis of neurocysticercosis according to Del Brutto et al. [20].
Diagnostic criteria for neurocysticercosis
Absolute 1. Histological demonstration of the parasite from biopsy of a brain or spinal cord lesion
2. Cystic lesions showing the scolex on CT or MRI
3. Direct visualization of subretinal parasites by funduscopic examination
Major 1. Lesions highly suggestive of neurocysticercosis on neuroimaging studies*
2. Positive serum EITB{ for the detection of anticysticercal antibodies
3. Resolution of intracranial cystic lesions after therapy with albendazole or praziquantel
4. Spontaneous resolution of small single enhancing lesions`
Minor 1. Lesions compatible with neurocysticercosis on neuroimaging studies1
2. Clinical manifestations suggestive of neurocysticercosis\
3. Positive CSF ELISA for detection of anticysticercal antibodies or cysticercal antigens
4. Cysticercosis outside the CNS"
Epidemiological 1. Evidence of a household contact with Taenia solium infection
2. Individuals coming from or living in an area where cysticercosis is endemic
3. History of frequent travel to disease endemic areas
Degree of certainty for the diagnosis of neurocysticercosis**
Definitive 1. Presence of one absolute criterion
2. Presence of two major plus one minor and one epidemiologic criterion
Probable 1. Presence of one major plus two minor criteria
2. Presence of one major plus one minor and one epidemiologic criterion
3. Presence of three minor plus one epidemiologic criterion
Footnotes:
CT: Computed Tomography, MRI: Magnetic Resonance Imaging, EITB: Enzyme-linked immunoelectrotransfer blot assay, CSF: Cerebrospinal Fluid, ELISA: Enzyme-linked
immunosorbent assay, CNS: Central Nervous System.
*CT or MRI showing cystic lesions without scolex, enhancing lesions, or typical parenchymal brain calcifications.
{Enzyme-linked immunoelectrotransfer blot assay using purified extracts of Taenia solium antigens, as developed by the Centers for Disease Control and Prevention
(Atlanta, GA).
`Solitary ring-enhancing lesions measuring less than 20 mm in diameter in patients presenting with seizures, a normal neurologic examination, and no evidence of an
active systemic disease.
1CT or MRI showing hydrocephalus or abnormal enhancement of the leptomeninges, and myelograms showing multiple filling defects in the column of contrast
medium.
\Seizures, focal neurologic signs, intracranial hypertension, and dementia.
"Histologically confirmed subcutaneous or muscular cysticercosis, plain X-ray films showing ‘‘cigar-shaped’’ soft-tissue calcifications, or direct visualization of cysticerci
in the anterior chamber of the eye.
**The presence of two different lesions highly suggestive of neurocysticercosis on neuroimaging studies should be considered as two major diagnostic criteria.
However, positive results in two separate types of antibody detection tests should be interpreted only on the basis of the test falling in the highest category of
diagnostic criteria.
doi:10.1371/journal.pone.0069537.t001
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example if sufficient data to classify the case as definitive or
probable were not available);
N Confirmed case of T. solium taeniasis: T. solium taeniasis case in
which the diagnosis was based on the detection of gravid
proglottids with information on the number of the uterine
branches or case in which the diagnosis of Taenia spp. was done
in a patient with cysticercosis or NCC;
N Possible case of T. solium taeniasis: T. solium taeniasis case
reported by the authors as ‘‘cases of T. solium taeniasis’’, but
not fulfilling the criteria of confirmed case;
N Autochthonous case: case diagnosed in a subject without history of
travel to or living in high endemic regions (Latin America, Asia
or Africa). A case in which the subject travelled in Europe was
considered autochthonous;
N Imported case: case diagnosed in a subject with a history of travel
or long stay in a endemic region (Latin America, Asia or
Africa).
Results
The flow diagram in Figure 1 shows the number of papers
identified in each database and the review process. Out of 1967
screened documents, 166 were included: 40 on autochthonous
cysticercosis [17,21–58], 7 on both autochthonous and imported
cysticercosis [19,59–64], 16 on autochthonous T. solium taeniasis
[65–80], 97 on imported cysticercosis [81–176], [Bartoloni A.
unpublished], 4 on imported cysticercosis and T. solium taeniasis
[7,177–179], and 2 on hospitalization for cysticercosis in Spain
and Italy [180,181].
Autochthonous Human Cysticercosis in Europe
Information on autochthonous cysticercosis originated from 47
papers [17,19,21–64]. According to a three year prospective study
on the etiology of adult-onset epilepsy, carried out in Extremadura
(Spain), 6.3% (5 of 80) of new cases of epilepsy were related to
neurocysticercosis [57]. According to a seroprevalence study on 770
patients with epilepsy resident in Croatia, the seroprevalence was
1.5% using an ELISA test confirmed by an EITB (Enzyme-linked
Figure 1. Flow diagram showing the number of papers identified in each database and the review process. Legend:
ECCMID = European Congress of Clinical Microbiology and Infectious Diseases; MoH = Ministry of Health; COHEMI = COordinating resources to
assess and improve HEalth status of MIgrants from Latin America.
doi:10.1371/journal.pone.0069537.g001
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Immunoelectrotransfer Blot) [182]. The other studies were case
reports or case series (Tables 2, 3, 4 and Figure S1).
Autochthonous T. solium taeniasis in Europe
Only a confirmed case of T. solium taeniasis in a 25 years old
Italian farmer, was documented [65]. In this case the authors
explicitly specified that the diagnosis was based on observation of a
several series of proglottids identified as T. solium. Forty-six cases of
possible T. solium taeniasis were reported from Poland, with at least
two cases per year in the period 1997–2008 [69–80], while no
cases were reported in 2009 [68]. In Albania, from 1982 to 2002,
18 possible cases of T. solium were documented in 20 districts
[67].The only available study on the prevalence of T. solium
taeniasis was done in Szczecin Province (Poland) from 1994 to
1998. Only three T. solium taeniasis cases of 331 intestinal
taeniasis, mainly due to T. saginata (n = 315), were documented. In
this survey, prevalence of unspecified taeniasis decreased from
10.33/100,000 in 1994 to 3.52/100,000 in 1998 [66].
Imported Human Cysticercosis in Europe
There are only two studies on anti-cysticerci IgG in adopted
children [172,179].
In Florence (Central Italy), 1090 adopted children, with a mean
age of 563.4 years, were tested for anti-cysticerci IgG by a
commercial EITB kit from 2001 to 2010, and the overall
seroprevalence was 1% (0.3%, 1.8%, 1.6%, 0% in Asian, Latin
American, African and European adopted children respectively).
Mean age of seropositive children was higher than that of
seronegative children (863.7 vs 563.3; p = 0.045). All seropositive
infants (n = 11) underwent a neuroimaging study (CT scan or
magnetic resonance imaging, MRI). Three presented abnormal
findings compatible with neurocysticercosis, but only one had
symptoms (epilepsy). The symptomatic child was a Peruvian
female presenting also T. solium tapeworm in stool [179].
In Negrar (Northern Italy), serum samples from 842 adopted
children were tested to detect anti-T. solium IgG by a commercial
Enzyme-linked Immunosorbent Assay (ELISA) (91), or EITB (12)
or both tests (739), from 2001 to 2008; of them, 87 sera tested
positive at least by one test (76 sera, 9.0%, by ELISA; 12 sera,
1.6% by EITB). When both tests were used, positive results were
discordant for all sera but one (1 ELISA+/EITB+; 64 ELISA+/
EITB-; 11 ELISA+/EITB not done; 11 EITB+/ELISA-). All the
87 seropositive infants underwent a cerebral MRI. Eight
(4 EITB+/ELISA-, 2 ELISA+/EITB not done, 2 ELISA+/
EITB-) showed abnormal findings which were compatible with
NCC, but only three had symptoms (epilepsy). The two children
with ELISA+/EITB- sera showed a single enhancing lesion and a
lesion compatible with a gliotic scar by MRI. The seroprevalence
of anti-T. solium IgG in sera of Asian, Latin American, African and
European adopted children was 10.0%, 7.6%, 5.2%, 10.7% by
ELISA and 1.7%, 0.0%, 2.6%, 0.0% by EITB, respectively [172].
Out of 108 studies, 324 cases of imported cysticercosis were
described [7,19,59–64,81–170,172,174–179], [Bartoloni A., un-
published]; of them, 242 (74.7%) were migrants, 57 (17.6%)
travellers, while no information was available for 25 cases (7.7%).
Eleven (44.0%) travellers acquired the infection in Latin America,
10 (40.0%) in Asia (5 of whom in India), and 4 (16.0%) in Africa.
The information was not available for 24 travellers or they had
visited two or more endemic regions. Among migrants, 12 (5.1%)
lived in more than one country before settling in Europe,
therefore, it was not possible to know where they become infected.
The majority of migrants (157; 69.8%) were Latin American
(including 86 from Ecuador, 18 from Peru, and 17 from Bolivia),
while the others were equally distributed between Africa (34,
15.1%, including 11 from Capo Verde and 6 from Madagascar),
and Asia (34, 15.1%, including 18 from India). The time elapsed
between the last exposure in an endemic country and the onset of
symptoms was reported for 158 subjects. Among them, 33 (22.9%)
developed symptoms within one year from the last exposure, 106
(73.6%) between 2 and 5 years, 11 (7.6%) between 6 and 10 years
and 8 (5.6%) after 11 or more years (Table 2, 3, 4 and Figure S1).
The majority of imported cases of cysticercosis were diagnosed in
Spain (47.5%), France (16.7%), Italy (8.3%) and United Kingdom
(7.4%). Seventy to 80% of imported cases in Spain and Italy were
diagnosed after 2000 while 80 to 90% of imported cases in France
and the United Kingdom were diagnosed before 2000.
Imported T. solium taeniasis in Europe
Only five confirmed cases of T. solium taeniasis were
documented in patients with cysticercosis. An African migrant
died due to a disseminated cysticercosis following the ingestion of
an adult T. solium tapeworm, a procedure suggested by an African
healer to treat abdominal pain and nausea. Two mature segments
of T. solium were recovered from faeces of this person [7]. The
second case was a Latin American person with NCC in which the
diagnosis was done through observation of gravid proglottids
[177]. In the other three cases of T. solium taeniasis reported in the
literature, the parasitological details of diagnosis were not specified
but all were diagnosed in persons with NCC. Two cases were
reported in migrants of unknown origin [178] and one in a
Peruvian child [179].
Hospitalization for Cysticercosis in Italy and Spain
According to the Italian MoH, the number of hospitalizations
for cysticercosis ranged between 40 and 53 per year in the period
2001–2010 [181]. The number of hospitalizations for migrants
showed an increasing temporal trend while a decreasing trend was
observed for Italians. From 2006 ongoing, the number of migrants
hospitalized for cysticercosis has exceeded that of Italians. Using
Table 2. Selected studies reporting autochthonous and
imported cases of cysticercosis in Europe (1990–2011 July).
Autochthonous Imported
Number of studies 46 108
Date of publication
1990–1994 14/46 (30.4%) 16/108 (14.8%)
1995–1999 6/46 (13.0%) 20/108 (18.5%)
2000–2004 14/46 (30.4%) 28/108 (25.9%)
2005–2009 11/46 (23,9%) 35/108 (32.4%)
2010–2011 July 1/46 (2.1%) 91/108 (8.3%)
First author field of activity
Neurology 15/44 (34.1%) 16/103 (15.5%)
Neurosurgery 8/44 (18.2%) 11/103 (10.7%)
Infectious Diseases 4/44 (9.1%) 19/103 (18.4%)
Pathology or Microbiology or
Parasitology
4/44 (9.1%) 9/103 (8.7%)
Pediatrics 1/44 (2.3%) 11/103 (10.7%)
Neuroradiology 2/44 (4.5%) 7/103 (6.8%)
Ophtalmology 1/44 (2.3%) 7/103 (6.8%)
Other 9/44 (20.4%) 23/103 (22.3%)
Footnotes:
1. One study is still unpublished [Bartoloni A. unpublished].
doi:10.1371/journal.pone.0069537.t002
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Table 3. Main features of autochthonous and imported cases of cysticercosis in Europe (1990–2011 July).
Autochthonous Imported
Number of cases 5221 3242
Case diagnostic certainty
definitive 33/496 (6.7%) 127/292 (43.5%)
probable 29/496 (5.8%) 66/292 (22.6%)
possible 434/496 (87.5%)3 99/292 (33.9%)
Male sex 85/189 (45%) 144/236 (61%)
Mean age 46.7616.1 32.0614.2
Main symptoms
asymptomatic 182/384 (47.4%) 12/236 (5.1%)
epilepsy 166/384 (43.2%) 162/236 (68.6%)
severe headache 14/384 (3.6%) 39/236 (16.5%)
others 22/384 (5.7%) 23/236 (9.7%)
Main localization of cysts
Central Nervous System (CNS) 492/496 (99.2%) 276/292 (94.5%)
eye 1/496 (0.2%) 10/292(3.4%)
skin or soft tissues 3/496 (0.8%) 6/292 (2%)
Parasitological examination of stool showing taeniasis 0/30 (0%) 5/133 (3.8%)
Neuroimages pattern4
cyst with scolex 3/276 (1.1%) 38/188 (20.2%)
cysts without scolex 75/276 (27.2%) 54/188 (28.7%)
enhancing lesions 23/276 (8.3%) 49/188 (26%)
calcifications 170/276 (61.6%) 65/188 (34.6%)
hydrocephalous 9/276 (3.3%) 14/188 (7.4%)
abnormal enhancement of leptomeninges 3/276 (1.1%) -
others 2/276 (0.7%) 9/188 (4.8%)
Serology
positive on serum5 60/94 (63.8%) 142/214 (66.4%)
positive on cerebrospinal fluid6 11/16 (68.7%) 48/69 (69.6%)
Treatment
surgery only 23/115 (20%) 19/254 (7.5%)
surgery+antiparasitic 23/115 (20%) 32/254 (12.6%)
antiparasitic only 59/115 (51.3%) 172/254 (67.7%)
neither surgical nor antiparasitic treatment 10/115 (8.7%) 31/254 (12.2%)
Indication for surgery (in neurocysticercosis)
ventriculo-peritoneal shunt for hydrocephalous 8/29 (27.6%) 16/46 (34.8%)
poor response to medical treatment 1/29 (3.4%) 2/46 (4.3%)
excisional or incisional biopsy for suspected CNS neoplasm 12/29 (41.4%) 15/46 (32.6%)
spinal cyst 3/29(10.4%) 3/46 (6.5%)
resections of ocular lesion 1/29 (3.4%) 6/46 (13%)
excision of intraventricular cyst 2/29 (6.9%) 3/46 (6.5%)
giant subarachnoid cyst 2/29 (6.9%) 1/46 (2.2%)
Notes:
1Cases published between 1990 and 2011 July but referred to cases diagnosed between 1980 and 2006. The majority (366, 70.1%) were diagnosed in Portugal from
1983 to 1994 [34,64].
2Cases published between 1990 and 2011 July but referred to case diagnosed between 1981 and 2009.
3Among this group, 348 subjects reported by Monteiro [34] were classified as ‘‘true’’ or probable, according to other criteria proposed by the same author in a previous
paper [203].
4Each subject may have more than one neuroimaging pattern.
5EITB was used in 7 autochthonous and in 41 imported cases with positive serology on serum.
6EITB was used in 5 autochthonous and in 9 imported cases with positive serology on CSF.
doi:10.1371/journal.pone.0069537.t003
Cysticercosis in Europe, Systematic Review
PLOS ONE | www.plosone.org 6 July 2013 | Volume 8 | Issue 7 | e69537
the number of hospitalizations by citizenship and by year as
numerator and the number of residents in Italy by citizenship and
by year as denominator [183], it was possible to estimate the
hospitalization rate by 100,000 subjects in different groups.
Considering the period 2001–2010, the higher mean hospitaliza-
tion rate has been found in citizens from Latin America (5.9/
100,000) and Asia (1.64/100,000), especially in Ecuadorian,
Bolivian, Indian and Peruvian people (Table 5). According to
the Spanish MoH from 2001 to 2009, the number of hospitaliza-
tions for suspected cases of cysticercosis ranged from 75 to 95 per
year [180].
Discussion
The results of our findings, about epidemiology of T. solium
taeniasis and cysticercosis in Europe, update those previously
published by Overbosch et al. [184] and supplement those
recently published by Del Brutto focusing on the epidemiology
of NCC in Western Europe [185]. With respect to the latter
review, our systematic research strategy included also grey
literature and data from Eastern European countries, it was not
limited to the CNS involvement, and focussed also on T. solium
taeniasis. Moreover, data on the diagnostic and therapeutic
management of the reported cases were also recorded.
Autochthonous cases of cysticercosis most of which were
diagnosed in persons from the Mediterranean region (Iberian
Peninsula, Italy and Balkans), are decreasing. In fact, most of these
cases (366, 70.1%) were reported in Portugal from 1983 to 1994
[34,64]. Persons who acquired cysticercosis in Europe were older
than those who acquired cysticercosis abroad, and were more
frequently asymptomatic, often presenting brain calcifications (the
end-stage inactive lesion of cysticercosis) and without taeniasis.
These clinical data suggest that these people acquired the infection
in a remote past.
Our literature investigation does not allow to know whether the
T. solium cycle is still active in Europe. Since T. solium taeniasis is
acquired by eating insufficiently cooked pig meat with cysticerci,
the presence in the European regions of porcine cysticercosis is the
‘‘condition sine qua non’’ to acquire T. solium taeniasis in Europe.
The importation of cysticercus-infected pork can be excluded due
to the veterinary controls, through meat inspection performed at
slaughterhouse, and the circulation of cysticercus-infected pigs
exists only in small and poor areas of the world where pigs are used
only for local consumption and which do not trade at the
international level.
Our search retrieved 68 cases of T. solium taeniasis in native
European persons, the large majority of which (67.6%) have been
reported from Poland. At the diagnosis, T. solium taeniasis may be
confused with the very common T. saginata which is circulating
with a 0.01–2% prevalence in Western Europe and with a higher
prevalence in Eastern Europe [186]. By morphology, T. solium and
T. saginata eggs are indistinguishable between them and the two
Taeniidae species can be distinguished only by the count of the
uterine branches in the proglottids or by the scolex which,
however, is very rarely detectable [187]. Specific faecal antigen
detection or PCR method are not yet performed in clinical
practice and, to our knowledge, were never used for an
epidemiological study in Europe.
To date in Western Europe, intensive indoor pig productions
largely predominate. However, the increasing trend to produce
organic pork from free-ranging pigs could increase the risk of T.
solium transmission [188], and could represent a reason of concern
for the control of cysticercosis in Europe. In 2007, a survey of the
European Food Safety Authority, among European Union
countries members, showed that porcine cysticercosis was still
diagnosed in five countries (Austria, Estonia, Lithuania, Poland
and Romania), no cases of porcine cysticercosis were reported in 9
countries (Belgium, Czech Republic, Denmark, Germany, Italy,
Luxembourg, the Netherlands, Portugal and the United King-
dom), whereas no information was available for the other 11 EU
countries [18]. This survey suggests that T. solium taeniasis is still
circulating in Europe; however, these data should be carefully
interpreted because porcine cysticercosis due to the larval stage of
Taenia hydatigena can be misdiagnosed with the infection caused by
larvae of T. solium. The absence of porcine cysticercosis recently
reported in Portugal [18], where an hotspot of cysticercosis
transmission was observed up to early nineties [34], suggests the
possible interruption of transmission due to the modification of
breeding conditions adopted in the recent years. Autochthonous
cases of cysticercosis in Europe could also originate from T. solium
carriers (migrant or traveller) who acquired taeniasis outside
Table 4. Autochthonous and imported cases of cysticercosis
in Europe by country of diagnosis (1990–2011 July).
Autochthonous Imported
Number of cases 522 324
Country of diagnosis
Austria 1/522 (0.2%) 1/324 (0.3%)
Belgium – 1/324 (0.3%)
Croatia 8/522 (1.5%) –
Czech Republic – 10/324 (3.1%)
Denmark – 1/324 (0.3%)
Finland – 1/324 (0.3%)
France 2/522 (0.4%) 54/324 (16.7%)
Germany 7/522 (1.3%) 15/324 (4.6%)
Greece 3/522 (0.6%) –
Hungary – 2/324 (0.6%)
Ireland – 2/324 (0.6%)
Italy 7/522 (1.3%) 27/324 (8.3%)
Latvia 1/522 (0.2%) 1/324 (0.3%)
Luxemburg 1/522 (0.2%) –
Norway 1/522 (0.2%) 3/324 (0.9%)
Poland 8/522 (15.3%) –
Portugal 366/522 (70.1%) 20/324 (6.2%)
Spain 35/522 (6.7%) 154/324 (47.5%)
Serbia 78/522 (14.9%) –
Switzerland 2/522 (0.4%) 4/324 (1.2%)
The Netherland – 4/324 (1.2%)
Turkey 1/522 (0.2%) –
United Kingdom 1/522 (0.2%) 24/324 (7.4%)
Notes:
Cases reported from Austria [39], Luxemburg [23], Norway [59], Switzerland [29],
two case from Germany [31,38] and one case from Spain [61] were diagnosed in
subjects who travelled to or resided in other European countries. Concerning
348 cases reported from Portugal [34], the authors do not specify whether all
cases are autochthonous, but state in the introduction that the catchment area
of the hospital is highly endemic (district of Oporto and north inland).
No cases were reported from Albania, Andorra, Belarus, Bosnia and
Herzegovina, Bulgaria, Cyprus, Estonia, Lithuania, Malta, Monaco, Moldova,
Romania, San Marino, Slovakia, Slovenia, Sweden, Ukraine, Russia, Montenegro,
Iceland, Macedonia, Vatican State.
doi:10.1371/journal.pone.0069537.t004
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Europe as observed in the United States [8,14]. In our search, we
found only 5 cases of T. solium immigrant carriers. Consequently,
we can speculate that the risk of spreading cysticercosis in Europe
from an asymptomatic tapeworm carriers coming from abroad is
quite low even if it cannot be excluded.
The larval stage of Taenia crassiceps, Taenia multiceps and Taenia
serialis infecting canids as final host and rodents, rabbits, sheep and
goats as intermediate host can sporadically affect humans in
Europe. In some cases, neither pathological examination nor
serology can differentiate these parasites from T. solium cysticerci
[50]. Therefore, we cannot exclude that a portion of cases
diagnosed as cysticercosis in Europe has been caused by other
species of cestodes.
In Europe, the increasing number of migrants from low
resource countries (74.7% of cysticercosis imported cases) and
international travellers (17.6% of imported cases) resulted in an
increase of cysticercosis. Most of imported cases originated from
Latin America, where 44.0% of affected travellers and 69.8% of
affected migrants acquired the infection. Most of individuals with
imported disease developed symptoms after 2 to 5 years after
migration. This finding is quite similar to that obtained in the
classic epidemiological studies carried out in the sixties in English
soldiers returning from India [189], confirming that the incubation
period of cysticercosis, even if largely variable, is usually between 2
to 5 years.
The European countries where cysticercosis cases are more
often imported are those with larger immigration such as Spain,
France, Italy and the United Kingdom. Spain is the country
reporting the highest number of imported cases of cysticercosis,
probably because it hosts the largest number of Latin American
migrants in Europe.
Considering both autochthonous and imported cases, neurolo-
gists, infectious disease specialists, neurosurgeons, laboratory
specialists (microbiologists, parasitologists, pathologists), paediat-
rics and radiologists were the most often involved persons in the
management of people with cysticercosis in Europe. This wide
range of specialists confirms the need of knowledge in different
settings to manage cysticercosis. NCC is certainly the parasite
localization which is managed with more difficulties since there is
not a gold standard test for the diagnosis but only diagnostic
criteria and no treatment of choice but only recommendation to
tailor the therapy case by case [190].
From the clinical point of view, NCC does not shows any
pathognomonic signs or symptoms. On the contrary, it may
present with nearly all neurological signs or symptoms [191,192].
Neuroradiological images are pathognomonic only in few cases
when the scolex is visible in the cyst (named ‘‘cyst with dot’’ image)
[20]. Serological tests didn’t help too much. Several serological
assays to detect specific antibodies have been used for decades with
different and somewhat conflicting results [193,194]. Currently,
most centres use an EITB with purified glycoprotein antigens
[195], which can be performed on serum samples or on
cerebrospinal fluid (CSF) or use an ELISAs. The EITB sensitivity
in serum samples is equal to or better than that in CSF samples
[196]. Although EITB has 100% specificity and a sensitivity of
98% in patients with two or more cerebral lesions, up to 50% of
patients with a single brain lesion or with only calcified parasites
may test negative [197–199]. The main problem related to ELISA
on serum is the poor specificity which is reported around 70% or
less [194]. In any case, serological results must be carefully
interpreted together with the other diagnostic criteria. So far,
EITB positivity on serum is considered to be a major diagnostic
criterion and ELISA positivity on CSF a minor diagnostic criterion
[20]. Recently, a serum antigen detecting ELISA has been
reported to have an acceptable sensitivity (83–100%) and
specificity (84–96%) and proposed as an adjunctive tool for the
diagnosing NCC [200].
The diagnostic delay can be huge. In one person, NCC was
misdiagnosed with migraine, cluster headache, and viral menin-
gitis for 29 years after the onset of symptoms [111]. Parenchymal
NCC can be misdiagnosed with brain tumour and lead to
avoidable surgery as in the two cases reported by Bouillot [163].
About one third of neurosurgical operations reported in the
examined literature, were probably avoidable since the indication
to surgery was not among that are commonly accepted [201]. In
autochthonous and imported cases of cysticercosis, 41.4% and
32.6% of operations, respectively, were performed for suspected
CNS neoplasm. This high rate of neurosurgical interventions can
be attributed to the low awareness and experience in management
of the disease and the inadequacy of preoperative diagnostic tools
[43].
Table 5. Hospitalization for cysticercosis in Italy, 2001–2010 [181,183].
Number of hospitalizations for cysticercosis
(2001–2010)
Estimated mean hospitalization rate for cysticercosis by
citizenship (n/100,000) (2001–2010)
All residents in Italy 540 0.09
Italians citizens 276 0.05




Citizens of African countries 40 0.55
Citizens of Asian countries 78 1.64
Indians 64 10.18
Citizens of European countries (except Italy) 14 0.09
References:
162. Ministero della Salute Dipartimento della Qualità Direzione Generale Programmazione Sanitaria (2011) Dati estratti dalla banca dati delle schede di dimissione
ospedaliera anni 2001–2010 per il progetto COHEMI. DGPROG 1.9.b/3. Italy.
163. Istituto Nazionale di Statistica (2011) Cittadini stranieri. Bilancio Demografico e popolazione residente straniera al 31 dicembre per sesso e cittadinanza.
doi:10.1371/journal.pone.0069537.t005
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According to Ruiz [154], 22.8% (8 of 35) of persons received
albendazole in spite of not having antiparasitic treatment
indication. Finally, it should be stressed that the treatment of
NCC cannot be limited to surgery and/or antiparasitic drugs. The
symptomatic therapy including anti-inflammatory drugs (cortico-
steroids), analgesics, adequate antiepileptic treatment as for other
secondary epilepsies, represents the main measure in the
management of NCC, however, these important treatment issues
are rarely discussed in case reports [202].
Conclusions: in Europe we are currently observing the
overlapping of two epidemiological pictures of cysticercosis/T.
solium taeniasis: the autochthonous and the imported infections.
Autochthonous cases are disappearing, while imported cases are
rising as a consequence of travels and migrations. Given the lack of
systematic epidemiological data collection and disease reporting,
the magnitude of the phenomenon cannot be delineated.
Moreover, it is unclear if cases of imported T. solium taeniasis
are now generating autochthonous cases of cysticercosis but,
according to our search, it is probably a limited problem. In order
to get more information, policy makers should consider to include
cysticercosis among mandatory reportable diseases. From the
clinical point of view, NCC remains a challenge for clinicians
despite their full access to all the available tools for diagnosis and
management of the disease. The currently available diagnostic
tests and treatment options are frequently insufficient and research
activities in this field are strongly needed. Within a perspective of a
south-north and north-south cooperation, European health care
providers might benefit from a transfer of knowledge from expert
colleagues working in endemic areas and the development of
shared diagnostic process and therapeutic decisions would have
impact on the European health systems quality.
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